摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,2-dimethyl-5-ethoxymethyl-1,3-dioxane | 133384-72-2

中文名称
——
中文别名
——
英文名称
2,2-dimethyl-5-ethoxymethyl-1,3-dioxane
英文别名
5-(Ethoxymethyl)-2,2-dimethyl-1,3-dioxane
2,2-dimethyl-5-ethoxymethyl-1,3-dioxane化学式
CAS
133384-72-2
化学式
C9H18O3
mdl
——
分子量
174.24
InChiKey
QIOMKPCYZQLKJE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    27.7
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    2,2-二甲基-[1,3]二恶烷-5,5-二甲酸二乙酯吡啶 、 lithium aluminium tetrahydride 、 sodium chloride 作用下, 以 乙醚乙醇二甲基亚砜 为溶剂, 反应 30.0h, 生成 2,2-dimethyl-5-ethoxymethyl-1,3-dioxane
    参考文献:
    名称:
    Synthesis of 5,5′-dihydroxyleucine and 4-fluoro 5,5′-dihydroxyleucine, the reduction products of 4-carboxyglutamic and 4-carboxy-4-fluoroglutamic acids
    摘要:
    Schemes for the synthesis of 5-5'-dihydroxyleucine 3 and its 4-fluoro analog 7 involving the condensation of a suitable ''aminoacid moiety'' with 2,2-dimethyl-5-iodomethyl-1,3-dioxane 15D or its fluoro analog 27A were tested. The anion of the ethyl N-diphenylmethylene-glycinate 25 gave better yields of 3 than the classical anion of diethyl acetamidomalonate. This strategy could not be successfully applied to the synthesis of 7, which could be prepared by reduction of a suitably protected 4-fluoro-4-carboxyglutamate with BMS.
    DOI:
    10.1016/s0040-4020(01)80939-x
点击查看最新优质反应信息

文献信息

  • COMPOUND HAVING SATURATED SIX-MEMBERED RING AND ALKOXY GROUP OR ALKOXYALKYL GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT
    申请人:JNC Corporation
    公开号:EP3260450A1
    公开(公告)日:2017-12-27
    Provided is a liquid crystal compound satisfying at least one of physical properties such as high stability to light or the like, a high clearing point, low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy and large dielectric anisotropy, a liquid crystal composition containing the compound, and a liquid crystal display device including the composition. A compound is represented by formula (1). In formula (1), for example, R1 is alkyl having 1 to 12 carbons; ring A1, ring A2 and ring A3 are independently in which, X1 and X2 are independently -O- or -CH2-; Y1 is fluorine, -CF3 or -OCF3; Z1 and Z3 are independently a single bond, -CF2O- or -COO-; Z2 is a single bond, -CF2O- or -COO-; L1 and L2 are independently hydrogen or halogen; a is 0, 1, 2 or 3; and n1 and n2 are independently 0, 1 or 2.
    本发明提供了一种液晶化合物,该化合物至少满足以下物理特性中的一项:对光或类似物的高稳定性、高清澈点、液晶相的最低温度低、粘度小、适当的光学各向异性和较大的介电各向异性;一种含有该化合物的液晶组合物;以及一种包括该组合物的液晶显示设备。 一种化合物用式(1)表示。 例如,在式 (1) 中 R1 是具有 1 至 12 个碳原子的烷基; 环 A1、环 A2 和环 A3 分别独立 其中,X1 和 X2 独立地为-O-或-CH2-; Y1 是氟、-CF3 或 -OCF3; Z1 和 Z3 独立地为单键、-CF2O- 或 -COO-; Z2 是单键、-CF2O- 或 -COO-; L1 和 L2 独立地为氢或卤素; a 是 0、1、2 或 3;以及 n1 和 n2 独立地为 0、1 或 2。
  • Liquid crystal composition and liquid crystal display device
    申请人:JNC CORPORATION
    公开号:US10655065B2
    公开(公告)日:2020-05-19
    A liquid crystal compound comprising a specific compound having a positive dielectric anisotropy as the first component, and a specific compound having a low viscosity as a second component. Further, the liquid crystal compound may contain a specific compound having a positive dielectric anisotropy as the third component, a specific compound having a maximum temperature or a low viscosity as the fourth component, or a specific compound having a negative dielectric anisotropy as the fifth component.
    一种液晶化合物,包含作为第一组分的具有正介电各向异性的特定化合物和作为第二组分的具有低粘度的特定化合物。此外,液晶化合物还可包含作为第三组分的具有正介电各向异性的特定化合物、作为第四组分的具有最高温度或低粘度的特定化合物或作为第五组分的具有负介电各向异性的特定化合物。
  • LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE
    申请人:JNC CORPORATION
    公开号:US20180030349A1
    公开(公告)日:2018-02-01
    A liquid crystal compound comprising a specific compound having a positive dielectric anisotropy as the first component, and a specific compound having a low viscosity as a second component. Further, the liquid crystal compound may contain a specific compound having a positive dielectric anisotropy as the third component, a specific compound having a maximum temperature or a low viscosity as the fourth component, or a specific compound having a negative dielectric anisotropy as the fifth component.
  • COMPOUND HAVING ALKOXY GROUP OR ALKOXYALKYL GROUP, AND SATURATED SIX-MEMBERED RING, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE
    申请人:JNC CORPORATION
    公开号:US20180022999A1
    公开(公告)日:2018-01-25
    Provided is a liquid crystal compound satisfying at least one of physical properties such as high stability to heat, light or the like, a high clearing point, low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy and large dielectric anisotropy, a liquid crystal composition containing the compound, and a liquid crystal display device including the composition. A compound is represented by formula (1). In formula (1), for example, R 1 is alkyl having 1 to 12 carbons; ring A 1 , ring A 2 and ring A 3 are independently in which, X 1 and X 2 are independently —O— or —CH 2 —; Y 1 is fluorine, —CF 3 or —OCF 3 ; Z 1 and Z 3 are independently a single bond, —CF 2 O— or —COO—; Z 2 is a single bond, —CF 2 O— or —COO—; L 1 and L 2 are independently hydrogen or halogen; a is 0, 1, 2 or 3; and n 1 and n 2 are independently 0, 1 or 2.
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
    申请人:Azura Ophthalmics Ltd.
    公开号:US20200331896A1
    公开(公告)日:2020-10-22
    Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
查看更多